Mirum Pharmaceuticals, Inc. Cash and Cash Equivalents, Fair Value Disclosure
Mirum Pharmaceuticals, Inc. (MIRM) had Cash and Cash Equivalents, Fair Value Disclosure of $262.68 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $262.68M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $261.46M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $254.38M.
- 2025-09-30: Cash and Cash Equivalents, Fair Value Disclosure $230.14M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $262.68M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $261.46M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $254.38M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $230.14M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $188.37M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $182.26M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $202.97M 10-K · filed 2026-02-25 |
| 2024-09-30 | $195.82M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $208.62M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $281.87M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $278.12M 10-K · filed 2025-02-26 |
| 2023-09-30 | $297.32M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $285.00M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $41.03M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $24.23M 10-K · filed 2024-03-15 |
| 2022-09-30 | $31.06M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $46.62M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $43.85M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $28.42M 10-K · filed 2023-03-08 |
| 2021-09-30 | $52.51M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $84.08M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $89.22M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $139.78M 10-K · filed 2022-03-09 |
| 2020-09-30 | $46.24M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $81.28M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $70.66M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $10.62M 10-K · filed 2021-03-09 |
| 2019-09-30 | $28.72M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $31.65M 10-Q · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |